Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)

BACKGROUND: Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combination with capecitabine in pre-treated patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Petzer, Andreas, Hubalek, Michael, Petru, Edgar, Sandholzer, Margit, Andel, Johannes, Balic, Marija, Melchardt, Thomas, Hauser-Kronberger, Cornelia, Schmitt, Clemens A., Ulmer, Hanno, Greil, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529308/
https://www.ncbi.nlm.nih.gov/pubmed/34691243
http://dx.doi.org/10.1177/17588359211042301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529308/
https://www.ncbi.nlm.nih.gov/pubmed/34691243
http://dx.doi.org/10.1177/17588359211042301

Ejemplares similares